Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
| Autor: | Chia-Wei Yang, I-Ling Liu, Shun-Sheng Wu, Kun-Ching Chou, Siou-Ping Huang, Pei-Yuan Su, Hsu-Heng Yen, Yu-Chun Hsu, Yang-Yuan Chen, Ya-Huei Zeng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
RNA viruses
Cyclopropanes Male Cirrhosis Aminoisobutyric Acids Pyrrolidines Sustained Virologic Response Social Sciences Disease Hepacivirus Gastroenterology 0302 clinical medicine Chronic Kidney Disease Clinical endpoint Psychology Public and Occupational Health Pathology and laboratory medicine Sulfonamides Multidisciplinary Protease Inhibitor Therapy Hepatitis C virus Liver Diseases Hepatitis C Medical microbiology Middle Aged Vaccination and Immunization Pibrentasvir Nephrology Research Design 030220 oncology & carcinogenesis Viruses Medicine 030211 gastroenterology & hepatology Sensory Perception Female Pathogens Research Article medicine.medical_specialty Proline Clinical Research Design Science Lactams Macrocyclic Immunology Antiretroviral Therapy Gastroenterology and Hepatology Research and Analysis Methods Microbiology Antiviral Agents End stage renal disease 03 medical and health sciences Antiviral Therapy Leucine Internal medicine Quinoxalines Medical Dialysis medicine Renal Diseases Humans Retrospective Studies Medicine and health sciences Biology and life sciences Flaviviruses business.industry Pruritus Organisms Viral pathogens Cognitive Psychology Retrospective cohort study Glecaprevir Hepatitis C Chronic medicine.disease Hepatitis viruses Microbial pathogens Cognitive Science Kidney Failure Chronic Perception Benzimidazoles Adverse Events Preventive Medicine business Neuroscience |
| Zdroj: | PLoS ONE PLoS ONE, Vol 15, Iss 8, p e0237582 (2020) |
| ISSN: | 1932-6203 |
| Popis: | IntroductionChronic hepatitis C virus (HCV) infection is increasingly observed in patients with renal disease. With the introduction of glecaprevir/pibrentasvir (GLE/PIB) as a pan-genotype therapy for HCV, treatment efficacy is expected to rise.Materials and methodsThis retrospective study evaluated the efficacy and safety of GLE/PIB treatment in adults with HCV infection and end-stage renal disease (ESRD). The primary end point was sustained virological response (SVR) observed 12 weeks after completed treatment.ResultsWe enrolled 235 patients, including 44 patients with ESRD. Median age was 60 years, and 48% were males. Twenty-two percent had cirrhosis. HCV genotypes 1 (43%) and 2 (41%) were the most common. The overall SVR rate was 96.6%. Patients with ESRD were older than those without (67.6 years vs 58.3 years, p < 0.001) and trended toward having a higher prevalence of cirrhosis (32% vs 19%, p = 0.071). A significant proportion of patients with ESRD complained of skin itching during treatment (61% vs 26%, p < 0.001), and the SVR rate were similar between these two groups (95.45% vs 96.86%, p = 0.644).ConclusionsDespite a higher rate of pruritus among patients with ESRD, GLE/PIB-based therapy achieved similarly high SVR rates among patients with and without ESRD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|